

Esther H Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9387807/publications.pdf>

Version: 2024-02-01

22
papers

263
citations

932766

10
h-index

940134

16
g-index

22
all docs

22
docs citations

22
times ranked

333
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. <i>Drug Safety</i> , 2015, 38, 565-575. | 1.4 | 31 |
| 2 | Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 712-721. | 0.9 | 27 |
| 3 | Long-Term Risk of Acute Myocardial Infarction, Stroke, and Death With Outpatient Use of Clarithromycin: A Retrospective Cohort Study. <i>American Journal of Epidemiology</i> , 2018, 187, 786-792. | 1.6 | 27 |
| 4 | Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study. <i>Drug Safety</i> , 2017, 40, 531-542. | 1.4 | 21 |
| 5 | Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e1. | 1.2 | 21 |
| 6 | Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis. <i>Journal of Health Communication</i> , 2017, 22, 365-372. | 1.2 | 18 |
| 7 | Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β_2 -agonist regulation from 2005-2011. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 710-717. | 1.5 | 17 |
| 8 | Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. <i>Drug Safety</i> , 2019, 42, 1287-1295. | 1.4 | 13 |
| 9 | Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers â€” a cohort study using the Clinical Practice Research Datalink. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 340-347. | 0.9 | 12 |
| 10 | Validity of <sc>ICDâ€10â€CM</sc> diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 899-909. | 0.9 | 11 |
| 11 | Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 500-509. | 1.0 | 10 |
| 12 | Antidepressant medication dispensing among montelukast initiators. <i>Journal of Asthma</i> , 2013, 50, 990-995. | 0.9 | 9 |
| 13 | Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 430-441. | 0.4 | 9 |
| 14 | Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. <i>Epidemiology</i> , 2020, 31, 82-89. | 1.2 | 9 |
| 15 | A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. <i>Drug Safety</i> , 2021, 44, 743-751. | 1.4 | 7 |
| 16 | Characterization of Long-Acting Beta₂-Adrenergic Agonists Utilization in Asthma Patients. <i>Journal of Asthma</i> , 2012, 49, 1079-1085. | 0.9 | 6 |
| 17 | The US Food and Drug Administration’s drug safety recommendations and long-acting beta2-agonist dispensing pattern changes in adult asthma patients: 2003–2012. <i>Journal of Asthma and Allergy</i> , 2017, Volume10, 67-74. | 1.5 | 5 |
| 18 | Changes in emergency department visits for zolpidemâ€attributed adverse drug reactions after FDA Drug Safety Communications. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 352-356. | 0.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Long-acting beta2-adrenergic agonist in pediatric and adolescent asthma patients, 2003â€“2011. Journal of Asthma, 2014, 51, 1061-1067. | 0.9 | 3 |
| 20 | The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005â€“2011. Journal of Asthma, 2018, 55, 907-914. | 0.9 | 1 |
| 21 | The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 700-709. | 0.5 | 1 |
| 22 | Trend changes of national zolpidem users and exposure cases after FDA drug safety communications. Pharmacoepidemiology and Drug Safety, 2021, 30, 1551-1559. | 0.9 | 1 |